ASH 2021: GMMG-HD7 Trial Demonstrates Benefits of Adding Isatuximab to Chemotherapy for Newly Diagnosed Multiple Myeloma
The addition of isatuximab did not affect safety or the need for dose reductions of chemotherapy
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.